Your browser doesn't support javascript.
loading
Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma.
Mai, Wilson X; Gosa, Laura; Daniels, Veerle W; Ta, Lisa; Tsang, Jonathan E; Higgins, Brian; Gilmore, W Blake; Bayley, Nicholas A; Harati, Mitra Dehghan; Lee, Jason T; Yong, William H; Kornblum, Harley I; Bensinger, Steven J; Mischel, Paul S; Rao, P Nagesh; Clark, Peter M; Cloughesy, Timothy F; Letai, Anthony; Nathanson, David A.
Afiliación
  • Mai WX; Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA.
  • Gosa L; Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA.
  • Daniels VW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Ta L; Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA.
  • Tsang JE; Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA.
  • Higgins B; Pharma Research and Early Development, Roche Innovation Center, New York, New York, USA.
  • Gilmore WB; Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA.
  • Bayley NA; Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA.
  • Harati MD; Department of Pathology, David Geffen UCLA School of Medicine, Los Angeles, California, USA.
  • Lee JT; Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA.
  • Yong WH; Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los Angeles, California, USA.
  • Kornblum HI; Department of Pathology, David Geffen UCLA School of Medicine, Los Angeles, California, USA.
  • Bensinger SJ; Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los Angeles, California, USA.
  • Mischel PS; Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA.
  • Rao PN; Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los Angeles, California, USA.
  • Clark PM; Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los Angeles, California, USA.
  • Cloughesy TF; Department of Microbiology, Immunology, and Molecular Genetics, David Geffen UCLA School of Medicine, Los Angeles, California, USA.
  • Letai A; Ludwig Institute for Cancer Research, University of California San Diego, San Diego, California, USA.
  • Nathanson DA; Department of Pathology, David Geffen UCLA School of Medicine, Los Angeles, California, USA.
Nat Med ; 23(11): 1342-1351, 2017 Nov.
Article en En | MEDLINE | ID: mdl-29035366
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Proteína p53 Supresora de Tumor / Apoptosis / Glioblastoma / Citoplasma / Glucosa Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Proteína p53 Supresora de Tumor / Apoptosis / Glioblastoma / Citoplasma / Glucosa Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos